Vertex Pharmaceuticals

Open: 351.42 Close: 347.74 Change: -3.68

We programmed an AI to read Internet. This is what it found out about Vertex Pharmaceuticals Stock.

Are looking for the most relevant information about Vertex Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Vertex Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, share, Pharmaceuticals, revenue, drug, company, profit, and the most common words in the summary are: vertex, pharmaceutical, stock, price, market, kb, pdf, . One of the sentences in the summary was: CEO Reshma Kewalramani sold 7,828 shares of the businesss stock in …

Concept Map

Semantic Network

Stock Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis (CF) It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with.

Today's Summary

Vertex Pharmaceuticals 2q profit up on higher cystic fibrosis drug revenue. CEO Reshma Kewalramani sold 7,828 shares of the businesss stock in a transaction dated Monday, July 17th.

Today's News

Vertex Pharmaceuticals 2q profit up on higher cystic fibrosis drug revenue - marketwatch.com. Vertex pharmaceuticals 2Q profit up. on higher Cystic fibros drug revenue. Vertex Pharmaceuticals Inc. delivered earnings and revenue surprises of 104% and 347% for the second-quarter 2023 quarter. The company is a global biotechnology company that discovers and develops small-molecule drugs. The revenue for VX-548 is expected to reach an annual total of $157 mn by 2033 in the US based off GlobalDatas Expiry Model. The revenue was expected to hit $157 million in the U.S. Among the largest hedge funds holding Vertex Pharmaceuticalss share is Bridgewater Associates, LP. Bridgewater Associates holds shares valued at 64M. It appears that Morse Asset Management Inc now owns a total of 5,896 shares of Vertex pharmaceuticals stock, having purchased an additional 681 shares. Vertex Pharmaceuticals specializes in developing and commercializing therapies for cystic fibrosis (CF) patients. Norges Bank acquired a new stake worth $707.9 million during the fourth quarter of the previous year. Morgan Stanley increased its stake in shares of Vertex pharmaceuticals by 33.1%. CEO Reshma Kewalramani sold 7,828 shares of the businesss stock in a transaction dated Monday, July 17th. Barclays raised their target price on shares of Vertex Pharmaceuticals from $342.00 to $384.00 in a research report on Tuesday, May 2nd. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. The company trades on the NASDAQ under the ticker symbol VRTX.

Stock Profile

"Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."

Keywords

How much time have you spent trying to decide whether investing in Vertex Pharmaceuticals? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, share, Pharmaceuticals, revenue, drug, company, profit, and the most common words in the summary are: vertex, pharmaceutical, stock, price, market, kb, pdf, . One of the sentences in the summary was: CEO Reshma Kewalramani sold 7,828 shares of the businesss stock in a transaction dated Monday, July 17th.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #vertex #pharmaceutical #stock #price #market #kb #pdf.